Background: Patients with suspected heart failure (HF) often present first to general practitioners (GPs). Timely and accurate HF diagnosis and reliable prognostic information have remained unmet goals in primary care, where patient evaluation often relies on clinical assessment only. The Handheld-BNP program investigates whether additional use of portable echocardiography (ECHO) and point-of-care determination of B-type natriuretic peptide (BNP) improves the accuracy of HF diagnosis and aids risk prediction in primary care.

Methods And Results: A research network was established between 2 academic centers, 2 × 6 cardiologists, and 2 × 24 GPs inexperienced with ECHO and BNP. The Training Study investigates the feasibility of implementing GP use and interpretation of ECHO and BNP. After training, competence is assessed using multiple-choice testing (pass mark: > 80% correct diagnoses). In the cluster-randomized four-arm Screening Study, each GP passes in random order through four study arms: clinical assessment (CA), CA + BNP, CA + ECHO, and CA + ECHO + BNP. Cardiologists' diagnoses serve as reference. Primary endpoint is the rate of correct GP diagnoses per study arm. In the Prognostic Follow-Up Study, patients are followed up centrally for 72 months. Forty-four GPs were successfully trained. With 225 ± 34 (75 ± 3) and 233 ± 28 (81 ± 7) min, respectively, total ECHO (BNP) training times were similar between centers I and II. Furthermore, training results did not differ between centers.

Conclusions: Standardized training of limited duration enabled GPs to use ECHO and BNP for HF diagnosis. The Handheld-BNP program will provide robust evaluation of the diagnostic effectiveness and prognostic value of these tools in primary care.

Trial Registration: http://www.controlled-trials.com (ISRCTN23325295).

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00392-017-1181-3DOI Listing

Publication Analysis

Top Keywords

echo bnp
16
handheld-bnp program
12
bnp training
12
b-type natriuretic
8
natriuretic peptide
8
portable echocardiography
8
patients suspected
8
suspected heart
8
heart failure
8
primary care
8

Similar Publications

Angiotensin Receptor Neprilysin Inhibitor (ARNI) has not shown to be promising in Heart failure with preserved LVEF. Role of ARNI in Right ventricular systolic dysfunction with preserved LVEF needs to be evaluated. We took 50 patients with isolated RV systolic dysfunction and divided them into two groups of 25 patients each- Conventional treatment and ARNI in addition to conventional treatment.

View Article and Find Full Text PDF

Background And Objectives: Cryptogenic strokes account for 20%-25% of all ischemic strokes. Although atrial cardiopathy markers are more prevalent in the cryptogenic embolic stroke of undetermined source (ESUS) subgroup than in the nonembolic stroke subgroup, the utility of individual parameters in predicting cardioembolic sources needs to be studied further. We studied the clinical, imaging, and atrial cardiopathy markers in three ischemic stroke subtypes - large artery atherosclerosis (LAA), cardioembolism (CE), and cryptogenic ESUS - and their role in predicting the source of CE.

View Article and Find Full Text PDF
Article Synopsis
  • Hypereosinophilia (HE) is characterized by an eosinophil count over 1500 cells/microL in blood tests, confirmed by either blood tests or high eosinophil percentages in bone marrow samples. Hypereosinophilic syndrome (HES) involves organ damage due to eosinophils and can be classified as primary, secondary, or idiopathic.
  • Cardiac issues occur in 5% of acute cases and 20% of chronic cases of HES, presenting symptoms like heart failure and arrhythmias, but the severity of heart problems isn't always proportional to eosinophil levels.
  • Diagnosis of cardiac involvement relies on advanced imaging techniques, particularly
View Article and Find Full Text PDF
Article Synopsis
  • Chronic Heart Failure (CHF) affects over 6.5 million adults in the U.S., with more than 50% of patients having preserved left ventricle ejection fraction (HFpEF), but the role of right ventricle (RV) dysfunction in these patients is not well understood.
  • The study analyzed 26 HFpEF patients, dividing them into groups with normal sinus rhythm and atrial fibrillation, and assessed various RV functions through transthoracic ultrasound.
  • Results indicated that none of the echocardiographic parameters effectively marked RV function in HFpEF patients, with the exception of the Right Ventricular Index of Myocardial Performance (RIMP), which
View Article and Find Full Text PDF
Article Synopsis
  • The study aims to identify early predictors of cardiotoxicity in lymphoma patients receiving doxorubicin, using 2D-Echo global longitudinal strain (GLS) and cardiac biomarkers.
  • Among 40 evaluated patients, 7.5% developed cardiotoxicity, with older age and higher hypertension rates linked to increased risk.
  • A drop in GLS of more than 15% after three chemotherapy cycles is a significant predictor of potential cardiac dysfunction, while cardiac biomarkers did not effectively indicate cardiotoxicity.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!